Suvotol Tablet 방글라데시 - 영어 - DGDA (Directorate General of Drug Administration)

suvotol tablet

square pharmaceuticals plc, pabna - suvorexant - tablet - 10 mg

Belsomra Tablets 10mg (ベルソムラ錠10mg) 일본 - 영어 - すりの適正使用協議会 RAD-AR Council, Japan

belsomra tablets 10mg (ベルソムラ錠10mg)

msd k.k. - suvorexant - very pale green tablet, diameter: 6.4mm, thickness: 4.1mm

Belsomra Tablets 15mg (ベルソムラ錠15mg) 일본 - 영어 - すりの適正使用協議会 RAD-AR Council, Japan

belsomra tablets 15mg (ベルソムラ錠15mg)

msd k.k. - suvorexant - oval, white tablet, long diameter: 10.3mm, short diameter: 5.6mm, thickness: 4.0mm

ITRACAP itraconazole 100 mg capsule blister pack 오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

itracap itraconazole 100 mg capsule blister pack

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itracap is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.